IL-6 is a pleiotropic cytokine involved in many biological functions that affect tissues beyond the immune system and the vasculature. This multifunctional cytokine exerts its actions via the classic signalling pathway when it binds to the transmembrane IL-6 receptor (IL-6R) or via the trans-signalling pathway upon binding to the soluble form of IL-6R (sIL-6R). In general, classic IL-6 signalling is responsible for the anti-inflammatory properties of IL-6, whereas trans-signalling is responsible for the pro-inflammatory actions of IL-6. As a result, dysregulation of the IL-6 axis can lead to the onset or development of several disease states, particularly autoimmune and inflammatory disorders, including RA and GCA. This pathological role of IL-6 means that pharmacologic modulation of the IL-6 axis is a rational therapeutic approach; however, multiple predictable, but often underappreciated, effects on tissues and organs beyond the blood vessels may also occur.
Introduction
IL-6 is a 26 kDa, four-helical glycopeptide that was initially identified as a T cellderived cytokine capable of inducing B lymphocyte differentiation into Ig-producing cells and was named B cell stimulatory factor 2 [13] . Human B cell stimulatory factor 2 complementary DNA was cloned in 1986 [1] and was shown to be identical to several other molecules, including IFN-b2 [4], a 26 kDa protein produced by fibroblasts [5], a hybridoma/plasmacytoma growth factor [68] and a hepatocyte-stimulating factor [9, 10] . It soon became clear that these molecules were the same, now known as IL-6, which is produced by a range of hematopoietic and visceral somatic cells and is responsible for multiple biological activities.
Since its discovery, advances in research regarding the complex signalling pathways that are driven by IL-6 have improved our understanding of how these pathways regulate the diverse biological activities associated with this cytokine [3] . In recent years, IL-6 has also been implicated in pathological processes associated with a number of autoimmune and inflammatory disorders, including RA, vasculitis (e.g. GCA), PMR, systemic JIA and Castleman disease [11, 12] , highlighting inhibition of IL-6 signalling as a rational therapeutic target. For example, the human mAb tocilizumab (TCZ) inhibits IL-6 signalling by targeting the IL-6 receptor a (IL-6Ra) and was the first IL-6-targeted biologic agent to be approved for the treatment of various inflammatory disorders, including RA and systemic JIA [13] .
The present article will provide an overview of the biological functions of IL-6, along with its pathological role in chronic inflammatory disorders. In addition, pharmacological modulation of IL-6-mediated signalling pathways and the consequent broad downstream effects will also be discussed.
Biological functions of IL-6
IL-6 is a pleiotropic cytokine [14] that mediates several biological functions, including regulation of the immune system, regenerative processes, metabolism, bone homeostasis, cardiovascular protection and neural function. IL-6 plays an important role in the development and activation of the innate and adaptive immune system. In the innate immune system, IL-6 induces the differentiation of monocytes to macrophages instead of dendritic cells (DCs) [15] and is associated with immunosuppressive properties in DCs [16] . Many inflammatory responses in tissues are also initiated by IL-6, which promotes the infiltration and activation of mononuclear leucocytes while suppressing neutrophil infiltration [1720] . Furthermore, IL-6 signalling is associated with the upregulation of anti-apoptotic factors that promote T cell survival [2123] . Ig synthesis is also regulated by IL-6, which induces the differentiation of activated B cells into Ig-producing plasma cells and promotes the differentiation of T follicular helper cells and production of IL-21 [12, 24] . Additionally, IL-6 regulates the differentiation of naïve CD4 + T cells into effector T cell subsets, such as pathogen-specific effector Th17 cells, and inhibition of TGF-b-induced development of regulatory T cells (Tregs) [14, 25] . During inflammation, IL-6 stimulates hepatocytes in the liver, resulting in the production of acute phase proteins such as CRP, serum amyloid A, fibrinogen and a1-antichymotrypsin, while fibronectin, albumin and transferrin production is reduced [26] . As a result, acute phase proteins such as CRP are often used as biomarkers of inflammation. IL-6 also plays a role in other important biological functions. IL-6 may be involved in liver regeneration by promoting hepatocellular proliferation [27] . Studies in animal models have shown that IL-6 signalling mediates glucose metabolism by regulating hepatic control of insulin sensitivity and glucose tolerance [28, 29] along with glucagon-like peptide-1 production to maintain proper insulin secretion and glucose homeostasis [30, 31] . IL-6 also appears to be involved in the regulation of bone homeostasis by promoting osteoclast formation [32, 33] . Furthermore, IL-6 may be involved in neural activities, with sympathetic neurons producing and responding to this cytokine [34, 35] . Finally, an acute cellular response to injury in the heart results in the production of IL-6 and IL-6-related cytokines that protect cardiac myocytes from oxidative stress and apoptosis [3638] .
IL-6 signalling
The multiple functions of IL-6 are initiated when IL-6 forms a protein complex with the IL-6R and the ubiquitously expressed 130 kDa transmembrane protein gp130 [11, 12, 39, 40] . The binding of IL-6 to IL-6R induces homodimerization of gp130, which in turn triggers a downstream signalling cascade that includes Janus kinase (JAK), signal transducer and activator of transcription factor 3 (STAT3) and JAKSHP-2mitogen-activated protein kinase pathways [39, 40] . Activation of these pathways results in the stimulation of IL-6 responsive target gene expression, including proliferative, anti-apoptotic and acute phase protein genes [39, 40] . STAT3 also induces the expression of suppressor of cytokine signalling 1 and suppressor of cytokine signalling 3, which bind to phosphorylated JAK and gp130, respectively, leading to the termination of IL-6 signalling via a negative feedback loop [11, 39] .
The majority of human cell types are not responsive to IL-6 because expression of the 80 kDa transmembrane IL-6R is limited to hepatocytes, neutrophils, monocytes/ macrophages and some lymphocytes [11, 41] . However, IL-6 can also signal via a 5055 kDa soluble form of IL-6R (sIL-6R) found in human serum [11, 42] , which is generated either by translation of an alternatively spliced mRNA or cleavage of transmembrane IL-6R, resulting in a receptor lacking both transmembrane and cytoplasmic components [4345] . Upon binding of IL-6 to sIL-6R, the complex binds to membrane-bound gp130 [42], thus stimulating cells that do not express transmembrane IL-6R, such as endothelial and smooth muscle cells. This form of IL-6 signalling is known as IL-6 trans-signalling, whereas signalling via transmembrane IL-6R is known as IL-6 classic signalling ( Fig. 1) [3, 11] .
The IL-6 classic and trans-signalling pathways were analysed using two designer proteins, an IL-6/sIL-6R fusion protein (known as hyper-IL-6) [46] and a fusion protein of the soluble extracellular portion of gp130 with the constant portion of human IgG1 antibody (known as sgp130Fc) [4648] . In vitro and in vivo studies demonstrated that sgp130Fc inhibited the pro-inflammatory functions of IL-6 but did not affect IL-6 responses via transmembrane IL-6R, whereas IL-6-mediated metabolism in the liver and intestinal epithelial regeneration were mediated by transmembrane IL-6R [46] . These findings indicate that classic IL-6 signalling via transmembrane IL-6R drives anti-inflammatory or regenerative processes, such as STAT3-dependent regeneration of intestinal epithelial cells, along with activation of the hepatic acute phase response and inhibition of epithelial apoptosis [3, 46] . In contrast, IL-6 trans-signalling via sIL-6R is responsible for the pro-inflammatory functions of IL-6, including the recruitment of mononuclear cells, inhibition of T cell apoptosis and inhibition of Treg cell differentiation [3, 46] .
The pathological role of IL-6
Due to the pleiotropic nature of IL-6, dysregulation of this cytokine is implicated in the onset and development of several disease states, particularly autoimmune and chronic inflammatory diseases (Fig. 2) [11]. For example, IL-6-induced dominance of Th17 cells over Treg cells may contribute to the disruption of immune tolerance involved in the development of autoimmune and inflammatory diseases [12] . IL-6 also induces vascular endothelial growth factor production, which enhances angiogenesis and increases vascular permeability, both of which are considered pathological features often seen in synovial tissues of patients with RA [49] . Changes in the skin of patients with systemic sclerosis may also occur as a result of IL-6-mediated keratinocyte proliferation or the generation of collagen in dermal fibroblasts [50, 51] .
Clinically, IL-6 production has been shown to be dysregulated in chronic inflammatory diseases such as RA [ [58] .
IL-6 has also been implicated in other disease states. Prolonged exposure to high concentrations of serum amyloid A can lead to the development of amyloid A amyloidosis, which results in amyloid fibril deposition and the subsequent development of several chronic inflammatory disorders [59] . The production of hepcidin following stimulation of hepatocytes in the liver alters iron homeostasis and increases the risk of hypoferraemia or anaemia associated with chronic inflammation [60] . Bone resorption and osteoporosis may also develop when bone marrow stromal cells produce IL-6, which in turn stimulates the RANK ligand (RANKL), an essential factor for the differentiation and activation of osteoclasts [6163] . Additionally, IL-6 is a known modulator of the hypothalamicpituitaryadrenal axis, which is involved in the development of fatigue [64, 65] . Finally, IL-6 is involved in the development of systemic inflammation, which alters lipid composition and causes atherogenesis, thus increasing cardiovascular risk [66, 67] .
IL-6/IL-6R as a rational therapeutic target
Given the range of biological functions of IL-6 and its pathological role in several disease states, IL-6 or IL-6R was considered to be a rational therapeutic target. Studies using animal models of disease to evaluate the pathological role of IL-6 have demonstrated the potential of inhibiting the IL-6 signalling pathway in a number of inflammatory disease models. IL-6 transgenic mice exhibited a reduction in susceptibility to Castleman diseaselike symptoms following IL-6 blockade [68] . Similar findings were also observed with models of RA [6971], SSc [72] , experimental autoimmune encephalomyelitis [73] , autoimmune uveoretinitis [74] and inflammatory myopathies [75] .
Studies have demonstrated a correlation between elevated levels of IL-6 in the serum, synovial fluid and various tissues and disease activity in inflammatory diseases such as Castleman disease [53, 76] , RA [77] , JIA [78, 79] , SSc [80] , PMR [55] and GCA [56, 81] . In particular, IL-6 plays a major role in sustaining disease activity in GCA [82] and appears to be a sensitive biomarker of disease activity [56, 83] .
The findings from animal models and the observed associations between IL-6 levels and inflammatory disease activity support the pathological role of IL-6, thus providing the rationale for the development of pharmacological treatments that target IL-6 or IL-6R. This led to the development of the first humanized monoclonal antibody (subsequently named TCZ), which was designed to target IL-6Ra [84] . TCZ targets both transmembrane IL-6Ra and sIL-6Ra, thus inhibiting both IL-6 classic signalling in cells that express IL-6R (e.g. hepatocytes) and trans-signalling in cells that do not express IL-6R, blocking both pro-and antiinflammatory activities [11, 85] . This global inhibition prevents activation of the signalling cascade, resulting in several downstream effects, including circulation of myeloid DCs [86] , monocytes, serum macrophage migration inhibitor factor levels [86, 87] and Th17 cells, while increasing Tregs [88, 89] . The risk of anti-drug antibodies associated with TCZ treatment is low, most likely because it induces regulatory B cell expansion and decreases B cell hyperactivity and the number of peripheral memory B cells [9092] . Indeed, recent studies of patients with RA have reported rare cases of TCZ anti-drug antibodies, which were mostly present at low levels [9395] .
IL-6-targeted therapies for the treatment of inflammatory disorders
TCZ is the first approved IL-6-targeted biologic therapy that is indicated for the treatment of JIA and RA [13] . TCZ has also shown promise in other chronic inflammatory disorders, including GCA. Retrospective analyses and small case series of patients with GCA have reported the beneficial effects of TCZ in those with relapsing/refractory [9698] as well as newly diagnosed [99] disease. In May 2017, the US Food and Drug Administration approved the use of s.c. TCZ to treat adult patients with GCA. This approval was based on results of the phase 3, multicentre, randomized, double-blind, placebo-controlled Giant-Cell Arteritis Actemra (GiACTA) trial, which evaluated the efficacy and safety of TCZ in patients with GCA [100, 101] . Superior clinical efficacy (sustained remission) and glucocorticoid-sparing effects were observed in patients treated with weekly or every-other- week TCZ and a blinded prednisone taper compared with those receiving a prednisone taper alone [101] .
Since patients with inflammatory diseases will likely require extended treatment, long-term global IL-6 blockade of both classic and trans-signalling may be associated with potentially severe adverse effects given that IL-6 is involved in many vital biological functions. The pleiotropic activities of IL-6 mean that this cytokine is involved not only in activation of the immune system, but also a range of other biological functions (e.g. regenerative processes, regulation of metabolism, maintenance of bone homeostasis, cardioprotection). Therefore, blocking its pathological actions in vascular disease has the potential to adversely affect its protective functions in other tissues, particularly during prolonged use. A pooled analysis of data from phase 3 clinical trials evaluating TCZ in patients with RA was conducted to assess the longer-term safety profile of TCZ [102] . Adverse events observed in clinical trials of IL-6 blockade with TCZ included serious infections, opportunistic infections and gastrointestinal perforation [103] . However, the longer-term safety profile of TCZ over a mean treatment duration of 4.6 years was similar to that of phase 3 studies with a duration of up to 1 year [103] . Furthermore, safety results from the phase 3 GiACTA trial did not reveal any unexpected safety signals, with serious infections being the most commonly reported serious adverse event [101] .
A number of other agents that inhibit the IL-6 signalling pathway are currently undergoing development, including those that target IL-6 (sirukumab, olokizumab, clazakizumab, ALX-0061, EBI-029), those that target both transmembrane IL-6R and sIL-6R (TCZ, sarilumab, situximab, ALD518, NI-1201), those that target the sIL-6/IL-6R complex (FE 999301) and those that target JAK (tofacitinib, ruxolitinib, CpG-stat3 siRNA) (Fig. 3) [104] . All of these agents, with the exception of a soluble gp130 Fc fusion protein (FE 999301) that targets the soluble IL-6/IL-6R complex, block both classic and trans-signalling [104, 105] . The contrasting properties of IL-6 classic signalling (anti-inflammatory or regenerative) and trans-signalling (pro-inflammatory) suggest that selective inhibition of trans-signalling with agents such as FE 999301 may be of clinical benefit, as it does not affect classic IL-6 signalling, thus retaining certain IL-6-mediated homeostatic processes [104] . As a result, selective IL-6 trans-signalling inhibition during inflammation may allow classic IL-6 signalling to persist, providing therapeutic benefit by lowering the risk of certain adverse events associated with IL-6R-targeted agents (e.g. gastric perforation associated with diverticulitis) through the induction of intestinal epithelial cell regeneration or offering protection against bacterial infection by supporting the innate immune response through induction of the hepatic acute phase reaction [3, 104] .
Conclusions
IL-6 is a pleiotropic cytokine with manifold effects on tissue beyond the immune system and the vasculature. Signalling via the transmembrane and soluble forms of IL-6R enables IL-6 to exert both anti-inflammatory and pro-inflammatory actions via classic signalling and transsignalling, respectively, which drive several vital biological functions. However, the multifunctional role of IL-6 means ii46 https://academic.oup.com/rheumatology that dysregulation of this cytokine can result in the onset or development of several disease states. Therefore, interference with the IL-6 axis and other cytokines can be anticipated to have multiple predictable, but often underappreciated, effects on tissues and organs beyond the blood vessels. This provides the rationale for therapeutic targeting of the IL-6 signalling pathway. TCZ is the first approved IL-6-targeted biologic therapy for a number of inflammatory diseases, including Castleman disease, RA and JIA. In addition, TCZ was recently approved for the treatment of GCA, based on positive findings of the pivotal GiACTA trial. However, long-term follow-up of the GiACTA trial is required. Additional studies of other novel agents that target the IL-6 axis will provide further insights into the downstream effects that arise following manipulation of IL-6-mediated signalling pathways. 
